Demographics and baseline clinical data (intention to treat population)
| Treatment Group, n=22 | Control Group, n=26 | |
| Female | 9 (40.9) | 15 (57.7) |
| Age in years, median (IQR) | 46 (18) | 52 (13) |
| Heartburn | 22 (100) | 24 (92.3) |
| Regurgitation | 20 (90.9) | 22 (84.6) |
| Chest pain | 6 (27.3) | 4 (15.4) |
| LPR symptoms | 8 (36.4) | 14 (53.8) |
| Dysphagia | 15 (68.2) | 15 (57.7) |
| PPI standard dose/once daily | 6 (27.3) | 4 (15.4) |
| PPI standard dose/twice daily | 3 (13.6) | 2 (7.7) |
| PPI max dose/once daily | 8 (36.4) | 12 (46.2) |
| PPI max dose/twice daily | 5 (22.7) | 8 (30.8) |
| PPI response—good | 10 (45.5) | 6 (23.1) |
| PPI response—partial | 7 (31.8) | 11 (42.3) |
| PPI response—poor | 5 (22.7) | 9 (34.6) |
| Manometric hiatus hernia | 8 (36.4) | 7 (26.9) |
| Oesophagitis grade A/B | 5 (22.7) | 7 (26.9) |
Values are expressed as numbers (percentages) unless stated otherwise.
LPR, laryngopharyngeal reflux; PPI, proton pump inhibitor.